Notícias

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $28.39, moving 6.7% from the previous trading session.

At first glance, Hims & Hers Health, Inc. (NYSE:HIMS) delivered the kind of result that investors typically reward. Revenue grew 38%, full-year guidance was increased, and the company completed an acquisition that management says positions it as the world’s leading consumer health platform. That made the quarter look like another strong growth report, although the […]

Key TakeawaysGross margin at Hims & Hers has fallen for eight straight quarters, from 79% in September 2024 to 64% in the quarter ended June 2026, even as revenue grew 40% year over year in that same latest quarter. Reported EBITDA margin turned negative in the March 2026 quarter and stayed there in June, at negative 8.

Novo Nordisk A/S (NYSE:NVO) outlined an updated strategy at its Capital Markets Day centered on diabetes and obesity, expansion into blood and endocrine disorders, liver disease and cardiovascular conditions, and a growing focus on consumer-facing prescription medicine channels. The company said it

Quest Diagnostics (NYSE:DGX) CEO and President Jim Davis said the diagnostic testing company is exceeding the growth framework it outlined at its prior investor day, driven largely by organic growth, consumer-health demand and partnerships rather than a heavier-than-expected pace of acquisitions. D

Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The insider still retains significant holdings, valued at $8.5 million, despite the sale.

Hims & Hers Health has been hit with an FTC complaint and multiple securities class action lawsuits alleging improper sharing of sensitive health data and misleading billing practices, events that have already drawn regulatory scrutiny and legal pressure by mid‑2026. The allegations cut to the core of Hims & Hers’ telehealth model, putting its privacy assurances and subscription-based business practices under a spotlight that could reshape how it operates. Against this backdrop of FTC action...

In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $27.93, indicating a -3.07% shift from the previous trading day.

History says you should avoid HIMS stock right now

Hims & Hers Health is still growing rapidly, but whether that growth can translate into better economics could determine how much further the stock can climb.

The weight-loss opportunity now comes with a margin tradeoff

Investing.com -- JPMorgan revealed Friday that it has started coverage of Hims & Hers Health at Neutral, setting a December 2027 price target of $32 as it weighs the direct-to-consumer health platform's rapid growth against execution risks in its shift to branded weight-loss drugs.

Pump.fun launches Custom Pairs, letting creators launch tokens against stocks, crypto, metals, and more while earning fees in the paired asset.

Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $28.17, representing a +1.66% change from its previous close.

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.

TDOC's Integrated Care is driving profitability as chronic care gains traction, potentially making it the company's key earnings driver.

HIMS raised its 2026 revenue outlook after Q2 sales jumped 38.2%, but margin contraction and an $86.3 million net loss highlighted growth costs.

HIMS has entered the second half of 2026 with weight-loss, international and AI momentum, but margin pressure and FDA uncertainty remain.

The FDA reported more than 1,700 adverse events involving compounded Semaglutide and Tirzepatide

Hims & Hers Health (NYSE:HIMS) shares fell 3.2% after the FDA warned telehealth companies and compounding pharmacies over unapproved weight-loss drugs, including versions of semaglutide, tirzepatide and retatrutide. The agency said retatrutide and cagrilintide cannot legally be used in...

Wobbly start predicted Stock futures wobbled on Tuesday morning as investors weighed the fallout from the weekend's escalation in Iran, a jittery bond market and the growing chance the Fed might hike rates again. Dow and S&P 500 futures slipped around 0.5%, while Nasdaq-100 contracts...

Hims & Hers Health, Inc. (NYSE:HIMS) has entered Australia, marking its first expansion into the Asia-Pacific market. The move follows its acquisition of Australian digital-health platform Eucalyptus, which includes men’s health brand Pilot and women’s health brand Juniper. Hims is initially rolling out weight-loss and men’s health treatments, with plans to introduce women’s health services […]

Its deepest fall inside a market shock is not its deepest fall, and that gap is what a holder should size for.

Hims & Hers Health stock has surged over the last three years, yet recent share price setbacks and a mixed valuation score leave investors weighing how much of the story is already reflected in the current price. The stock is up about 3.2x over the past three years. That puts extra focus on whether that strong run can be supported by future business performance. Plans to expand into experimental peptide therapies may support higher long term growth expectations. At the same time, regulatory...

MarketBeat analysts recap a mixed earnings week, covering AI infrastructure demand, retail's K-shaped consumer trends, Meta's $18 billion settlement, and stock picks across tech, biotech, and retail sectors.

Earlier this week, Hims & Hers Health reported quarterly revenue of US$753.2 million, up 38.2% year on year, added 307,000 customers to reach 2.89 million, and raised both next-quarter revenue guidance and full-year EBITDA guidance above analyst expectations. Alongside these financial updates, new survey findings on Gen Z sexual health attitudes and ongoing regulatory and legal scrutiny of Hims & Hers’ privacy and billing practices highlight both expanding demand for its services and...

On August 18, 2026, Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum told CNBC that a Federal Trade Commission lawsuit over the company’s data-sharing and subscription practices “misunderstands how the company works.” He defended the company’s compounded GLP-1 drug sales as having helped lower prices for weight-loss treatments. Why This Matters Hims & Hers […]

On August 21, 2026, Bloomberg reported that Hims & Hers Health, Inc. (NYSE:HIMS) was enrolled in Visa Inc. (NYSE:V)’s Acquirer Monitoring Program after customer credit card disputes in its weight-loss subscription business exceeded acceptable levels in July. Each dispute carries an $8 surcharge, resulting in a bill of nearly $75,000 due in September, and Hims […]